La Jolla Pharmaceutical Co. (Nasdaq: LJPC) reported positive results from the ATHOS-3 Phase 3 study of LJPC-501 in patients with catecholamine resistant hypotension sending the stock price soaring $15.25 to close at $35.12.
La Jolla Pharmaceuticals reports positive study results
February 27, 2017 at 17:08 PM EST
